Charlie Swanton wins 2024 Louis-Jeantet Prize

Charlie Swanton, Deputy Clinical Director at the Crick, has been awarded the 2024 Jeantet-Collen Prize for Translational Medicine for his research in cancer genetics and evolution, leading to insights into how tumours evolve, spread, and develop resistance to drugs.

Charlie Swanton

Every year, the Louis-Jeantet Prizes distinguish leading-edge researchers who are active in the member states of the Council of Europe. When the research being recognised is close to practical applications for combating illnesses affecting humankind, one of the Louis-Jeantet Prizes converts into a Jeantet-Collen Prize for Translational Medicine.

Cancer research is team science and this award reflects the incredible work of my lab members and many colleagues at the Crick, UCL and Manchester and contributors across the world, and most importantly long-term funding support from Cancer Research UK, the Crick and the Rosetrees Trust.
Charlie Swanton

Dirk Görlich, Director at the Max Planck Institute for Multidisciplinary Sciences in Göttingen, Germany has also been awarded the 2024 award for Medicine.

Charlie has been recognised for how his research has transformed our understanding of cancer and how to treat it more effectively in the future. He and his team have provided insights into the driving forces and constraints that act on cancer as it evolves over time. 

His work leading the Cancer Research UK funded TRACERx study brings together more than 800 patients in clinical trials and a community of 250 investigators who based at 13 hospital sites across the UK. By looking at the tumour in its entirety, researchers can observe how cell populations interact and compete, which is providing valuable insights into how a tumour might evolve, spread and respond to treatment.

On receiving the news, Charlie said: “I am delighted to have been awarded this prestigious prize.

“Cancer research is team science and this award reflects the incredible work of my lab members and many colleagues at the Crick, UCL and Manchester and contributors across the world, and most importantly long-term funding support from Cancer Research UK, the Crick and the Rosetrees Trust.”

Paul Nurse, director of the Crick, said: “Congratulations to Charlie for this much deserved recognition of his contribution to cancer research, through his insights into the complexities of tumour evolution. 
 
“Charlie’s research stretches from the clinic to the lab and back, working to turn discoveries into improvements in tests and treatments for patients.”
 

Sign up for our newsletters

Join our mailing lists to receive updates about our latest research and to hear about our free public events and exhibitions.  If you would like to find out more about how we manage your personal information please see our privacy policy.